Dec 13, 2022 | John DeFlice
“The cause is hidden; the effect is visible to all.” Mike Horn Multiple myeloma is a cytogenetically complex blood cancer of the plasma cell, and thesecytogenetic aberrations make it more difficult to treat. Cytogenetics is the study of thebone marrow looking for...
Dec 13, 2022 | Jessie Daw
As I mentioned in my previous blog, the uncertainties of living with smoldering multiple myeloma (SMM) can be whittled down to two “million dollar” questions: (a) “Will I progress to active disease?” and (b) “Should I consider treatment, and if so, how and when?” This...
Dec 13, 2022 | Becky Bosley
Sunday brought so many exciting advances in investigating different facets of things that affect patient’s quality of life. I can truly say that during ASH, I heard researchers thank patients and their families an innumerable number of times. Researchers understand...
Dec 13, 2022 | Jack Aiello
Today was the final day of ASH, but it was still full of information, and to be honest, I’m a bit brain-fried. For me, the day started with an excellent Education Spotlight session on “Underrepresented minorities in clinical trials…”. It was chaired by multiple...
Dec 13, 2022 | Sheri Baker
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition is not only a meeting to share data and outcomes from clinical trials relating to new treatments, but also to discuss other topics affecting those with a hematologic cancer. One of those is...
Dec 12, 2022 | John DeFlice
“The impossible exists only until we find a way to make it possible.” Mike Horn Emily Whitehead was five years old when she was diagnosed with acute lymphoblastic leukemia (ALL). After being treated with chemotherapy for two years, she experienced a failure of therapy...
